Résumé :
|
[BDSP. Notice produite par INIST-CNRS R0x5hvZy. Diffusion soumise à autorisation]. Hepatitis A is one of the most common vaccine-preventable Infectious diseases in the world. Effective vaccines against hepatitis A have been available since 1992, and they provide long-term immunity against the infection. However, there is no worldwide consensus on how long protection will last or whether there will be a need for hepatitis A virus (HAV) booster vaccinations in the future. In most countries, booster-vaccination policy Is guided by manufacturers'recommendations, national authorities, or both. In June, 2002, a panel of international experts met to review the long-term immunogenicity and protection conferred by HAV vaccine in different population groups. Data have shown that after a full primary vaccination course, protective antibody amounts persist beyond 10 years in healthy individuals, and underlying immune memory provides protection far beyond the duration of anti-HAV antibodies. The group concluded that there Is no evidence to lend support to HAV booster vaccination after a full primary vaccination course In a healthy Individual. However, further investigations are needed before deciding if boosters can be omitted in special patient-groups.
|